RT Journal Article
SR Electronic
T1 Statin uses and skeletal muscle-related phenotypes: insights from epidemiological and Mendelian randomization analyses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.16.24313777
DO 10.1101/2024.09.16.24313777
A1 Tang, Fan
A1 Chen, Zhanchao
A1 Qiu, Hongbing
A1 Liu, Yige
A1 Shen, Yanjiao
A1 Zhang, Yiying
A1 Wang, Shanjie
A1 Yu, Bo
YR 2024
UL http://medrxiv.org/content/early/2024/09/19/2024.09.16.24313777.abstract
AB Background The association between statin use and skeletal muscle-related side effects is always controversial. This study aimed to comprehensively investigate the associations between statin use and muscle-related phenotypes including sarcopenia, sarcopenic obesity, serum lactate dehydrogenase (LDH), and musculoskeletal pain symptoms among adults with indications for statin use for secondary prevention (cardiovascular disease, diabetes, or hyperlipidemia).Methods This cross-sectional study included 22,549 patients aged ≥20 years with cardiovascular disease, diabetes, or hyperlipidemia. Weighted generalized linear regression analysis and propensity score matching methods were used to estimate the associations between the use of statins or other lipid-lowering agents and skeletal muscle-related phenotypes. Mendelian randomization (MR) analysis was additionally used to verify the causal relationship between statin use and skeletal muscle-related phenotypes.Results The weighted mean age was 59 years, 50.3% were male, and 37.6% (n=8,481) received statin treatment. In the unadjusted model, compared with adults without any lipid-lowering drugs, statin use was associated with a higher likelihood of sarcopenia (appendicular skeletal muscle mass [ASM]/Body mass index [BMI] OR 1.35 (95%CI 1.12 to 1.62, p < 0.001), ASM/weight [Wt] OR 1.86 (95%CI 1.62 to 2.13, p < 0.001), max HGS β -3.01 (95% CI -3.97 to -2.06, p < 0.001), relative HGS β -0.23 (95% CI -0.30 to -0.17, p < 0.001) and combined HGS β -5.90 (95% CI -7.86 to -3.93, p < 0.001)), sarcopenic obesity (ASM/height squared [Ht2] and body fat percentage definition [OR 1.36 (95% CI 1.13 to 1.63, p < 0.001]). After multivariable adjustment or propensity score match, the independent associations of statin use with sarcopenia, sarcopenic obesity, HGS, LDH, and musculoskeletal pain became nonsignificant. Stepwise regression suggested that age was the predominant confounding factor for the associations. MR analysis also revealed no significant causality between statin use and skeletal muscle-related phenotypes.Conclusions Our epidemiological and MR analyses did not support the causality between statin use and skeletal muscle-related phenotypes. A higher likelihood of skeletal muscle-related adverse phenotypes in statin users may be attributed to age. Future studies should further explore the biological factors that may affect statin-related muscle phenotypes to provide evidence for the safety of statins.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSW was funded by the National Natural Science Foundation of China (82200396), Natural Science Foundation of Heilongjiang Province of China (YQ2022H006), New era Longjiang outstanding doctoral key project (LJYXL2022-013), Cultivation Project of Second Affiliated Hospital of Harbin Medical University (PYMS2023-3); YZ was funded by the Gout Etiology and Functional Food Research Innovation Team, the North Medicine and Functional Food Characteristic Subject Project in Heilongjiang Province (HLJTSXK-2022-03), Postdoctoral Science Foundation of Heilongjiang Province of China (LBH-Q21047), National Fund Cultivation Program of Jiamusi University (JMSUGPZR2022-022), Scientific and Technological Innovation Team of Jiamusi University (cxtd202101).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving research study participants were approved by the [NCHS]. Written informed consent was obtained from all subjects.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets supporting the conclusions of this article are available in the National Health and Nutrition Examination Survey repository, unique persistent identifier and hyperlink to the dataset in https://wwwn.cdc.gov/nchs/nhanes/default.aspx.